Clinical trial Phase 2 Interventional Ages 18 and up

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Run by Radiation Therapy Oncology Group · NCT01220583 · Data updated 2026-11-12

Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2026-12-31.

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with chemotherapy or alone after surgery in treating salivary gland tumors. PURPOSE: This randomized phase II/III trial is studying radiation therapy with or without chemotherapy to see how well it works in treating patients with high-risk malignant salivary gland tumors t…

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment252 (actual)
SponsorRadiation Therapy Oncology Group
Research network
Drugs / interventionscisplatin, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
Locations268 sites (Canada, Saudi Arabia, United States)
Trial IDNCT01220583 on ClinicalTrials.gov

What this trial studies

OBJECTIVES: Primary Phase II * Determine the feasibility of conducting a cooperative group prospective clinical trial in patients with resected malignant salivary gland tumors. * Acquire preliminary efficacy data comparing postoperative radiotherapy alone to concurrent chemotherapy and radiation using weekly cisplatin. Phase III \* Compare overall survival rates among patients receiving cisplatin and radiation to those receiving radiation alone. Secondary Phase II/III * Compare the acute toxicities of these 2 adjuvant treatments. * Compare late treatment-related adverse events in patients receiving postoperative radiation to those receiving concurrent chemoradiation. * Compare progression-free survival rates among patients receiving cisplatin and radiation to those receiving radiation alone in both the cohort of patients with pathologically high-risk disease (high-grade adenocarcinoma, high-grade mucoepidermoid carcinoma, salivary duct carcinoma), and the patient cohort with pathologically intermediate-risk disease (all other eligible diagnoses). * Investigate quality of life and patient-reported outcomes in patients enrolled in the study. * Identify the histopathology and tumor marker expression from patients enrolled on this trial and assemble a tissue bank for future correlative studies. * Establish a NRG Oncology baseline database for salivary gland malignancies to serve as a resource for future exploration of innovative and/or targeted approaches for this disease…

Who can join: the full rules

Show full inclusion / exclusion criteria
DISEASE CHARACTERISTICS:

* Pathologically proven diagnosis of a malignant major salivary gland tumor or malignant minor salivary gland tumor of the head and neck of the following histologic subtypes:

  * Intermediate-grade adenocarcinoma or intermediate-grade mucoepidermoid carcinoma
  * High-grade acinic cell carcinoma or high-grade (\>30% solid component) adenoid cystic carcinoma
* Surgical resection with curative intent within 8 weeks prior to registration
* All patients must have a Medical Oncology evaluation within 4 weeks prior to registration
* Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (≤ 1mm) or microscopically positive surgical margin; patients must be free of distant metastases based upon the following minimum diagnostic workup:

  * History/physical examination within 8 weeks prior to registration
  * Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration; at a minimum, contrast CT imaging of the chest is required (PET/CT is acceptable)
* No patients with residual macroscopic disease after surgery
* No prior systemic chemotherapy or radiation therapy for salivary gland malignancy

PATIENT CHARACTERISTICS:

* Zubrod performance status 0-1
* Absolute neutrophil count (ANC) ≥ 1,800 cells/mm\^3
* Platelets ≥ 100,000 cells/mm\^3
* Hemoglobin ≥ 8.0 g/dL (the use of transfusion or other intervention to achieve hemoglobin ≥ 8.0 g/dL is acceptable)
* Serum creatinine \< 2.0 mg/dL
* Total bilirubin \< 2 x the institutional upper limit of normal (ULN)
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 3 x the institutional ULN
* Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential
* Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatment
* Not pregnant or nursing
* Patients must be deemed able to comply with the treatment plan and follow-up schedule
* Patients must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for central review
* No prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
* No severe, active co-morbidity, defined as follows:

  * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
  * Transmural myocardial infarction within the last 6 months
  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
  * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
  * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects (coagulation parameters are not required for entry into this protocol)
  * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition (HIV testing is not required for entry into this protocol)

    * Protocol-specific requirements may also exclude immunocompromised patients
  * Pre-existing ≥ grade 2 neuropathy
* No significant pre-existing hearing loss, as defined by the patient or treating physician

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior systemic chemotherapy or radiation therapy for salivary gland malignancy (prior chemotherapy for a different cancer is allowable)
* No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
* No prior organ transplant
* No concurrent hematopoietic growth factors (e.g., G-CSF or pegfilgrastim) during radiotherapy
* No concurrent erythropoiesis-stimulating agents

Where it's running

  • University of Alabama at Birmingham Cancer Center
    Birmingham, Alabama, United States
  • The Kirklin Clinic at Acton Road
    Birmingham, Alabama, United States
  • Arizona Breast Cancer Specialists-Gilbert
    Gilbert, Arizona, United States
  • Arizona Center for Cancer Care-Peoria
    Peoria, Arizona, United States
  • Cancer Center at Saint Joseph's
    Phoenix, Arizona, United States
  • Arizona Breast Cancer Specialists-Phoenix
    Phoenix, Arizona, United States
Show 44 more locations
  • Arizona Oncology-Deer Valley Center
    Phoenix, Arizona, United States
  • Arizona Breast Cancer Specialists
    Scottsdale, Arizona, United States
  • Arizona Breast Cancer Specialists-Scottsdale
    Scottsdale, Arizona, United States
  • Arizona Oncology Services Foundation
    Scottsdale, Arizona, United States
  • Arizona Center for Cancer Care-Surprise
    Surprise, Arizona, United States
  • University of Arizona Cancer Center-Orange Grove Campus
    Tucson, Arizona, United States
  • Banner University Medical Center - Tucson
    Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus
    Tucson, Arizona, United States
  • Sutter Cancer Centers Radiation Oncology Services-Auburn
    Auburn, California, United States
  • AIS Cancer Center at San Joaquin Community Hospital
    Bakersfield, California, United States
  • Mills-Peninsula Medical Center
    Burlingame, California, United States
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park
    Cameron Park, California, United States
  • Mercy San Juan Medical Center
    Carmichael, California, United States
  • City of Hope Comprehensive Cancer Center
    Duarte, California, United States
  • UC San Diego Moores Cancer Center
    La Jolla, California, United States
  • Los Angeles County-USC Medical Center
    Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California, United States
  • Fremont - Rideout Cancer Center
    Marysville, California, United States
  • Memorial Medical Center
    Modesto, California, United States
  • Hoag Memorial Hospital
    Newport Beach, California, United States
  • Saint Joseph Hospital - Orange
    Orange, California, United States
  • Stanford Cancer Institute Palo Alto
    Palo Alto, California, United States
  • Sutter Cancer Centers Radiation Oncology Services-Roseville
    Roseville, California, United States
  • Sutter Medical Center Sacramento
    Sacramento, California, United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California, United States
  • UCSF Medical Center-Mount Zion
    San Francisco, California, United States
  • UCSF Medical Center-Mission Bay
    San Francisco, California, United States
  • Sutter Cancer Centers Radiation Oncology Services-Vacaville
    Vacaville, California, United States
  • Rocky Mountain Cancer Centers-Aurora
    Aurora, Colorado, United States
  • University of Colorado Hospital
    Aurora, Colorado, United States
  • Boulder Community Hospital
    Boulder, Colorado, United States
  • Penrose-Saint Francis Healthcare
    Colorado Springs, Colorado, United States
  • Porter Adventist Hospital
    Denver, Colorado, United States
  • Swedish Medical Center
    Englewood, Colorado, United States
  • Rocky Mountain Cancer Centers-Littleton
    Littleton, Colorado, United States
  • Longmont United Hospital
    Longmont, Colorado, United States
  • McKee Medical Center
    Loveland, Colorado, United States
  • North Suburban Medical Center
    Thornton, Colorado, United States
  • Rocky Mountain Cancer Centers-Thornton
    Thornton, Colorado, United States
  • William Backus Hospital
    Norwich, Connecticut, United States
  • Helen F Graham Cancer Center
    Newark, Delaware, United States
  • Christiana Care Health System-Christiana Hospital
    Newark, Delaware, United States
  • Beebe Health Campus
    Rehoboth Beach, Delaware, United States
  • UM Sylvester Comprehensive Cancer Center at Coral Gables
    Coral Gables, Florida, United States

+218 more sites. See ClinicalTrials.gov for the full list.

Study contacts

  • Principal investigator: Cristina P. Rodriguez, MD — OHSU Knight Cancer Institute

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.